Philippe Jolliet1, Lamia Ouanes-Besbes2, Fekri Abroug2, Jalila Ben Khelil3, Mohamed Besbes3, Aude Garnero4, Jean-Michel Arnal4, Fabrice Daviaud5, Jean-Daniel Chiche5, Benoît Lortat-Jacob6, Jean-Luc Diehl6, Nicolas Lerolle7, Alain Mercat7, Keyvan Razazi8, Christian Brun-Buisson8, Isabelle Durand-Zaleski9, Joëlle Texereau5,10, Laurent Brochard9,11,12,13. 1. 1 Intensive Care and Burn Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 2. 2 Fattouma Bourguiba University Hospital, Monastir, Tunisia. 3. 3 Abderrahmen Mami Hospital, Ariana, Tunisia. 4. 4 Sainte Musse Hospital, Toulon, France. 5. 5 Cochin Hospital, Paris, France. 6. 6 Georges Pompidou European Hospital, Paris, France. 7. 7 Angers University Hospital, Angers, France. 8. 8 Henri-Mondor Hospital, Créteil, France. 9. 9 Institut national de la santé et de la recherche médicale, UMR 955, Université Paris Est, Créteil, France. 10. 10 Air Liquide Santé International, Medical R&D, Jouy-en-Josas, France. 11. 11 University Hospital of Geneva, Intensive Care Unit, Geneva, Switzerland. 12. 12 Li Ka Shing Institute and Keenan Research Centre, St Michael's Hospital, Toronto, Ontario, Canada; and. 13. 13 University of Toronto, Interdepartmental Division of Critical Care Medicine, Toronto, Ontario, Canada.
Abstract
RATIONALE: During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work of breathing and hypercapnia more than air/O2, but its impact on clinical outcomes remains unknown. OBJECTIVES: To determine whether continuous administration of heliox for 72 hours, during and in-between NIV sessions, was superior to air/O2 in reducing NIV failure (25-15%) in severe hypercapnic COPD exacerbations. METHODS: This was a prospective, randomized, open-label trial in 16 intensive care units (ICUs) and 6 countries. Inclusion criteria were COPD exacerbations with PaCO2 ≥ 45 mm Hg, pH ≤ 7.35, and at least one of the following: respiratory rate ≥ 25/min, PaO2 ≤ 50 mm Hg, and oxygen saturation (arterial [SaO2] or measured by pulse oximetry [SpO2]) ≤ 90%. A 6-month follow-up was performed. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was NIV failure (intubation or death without intubation in the ICU). The secondary endpoints were physiological parameters, duration of ventilation, duration of ICU and hospital stay, 6-month recurrence, and rehospitalization rates. The trial was stopped prematurely (445 randomized patients) because of a low global failure rate (NIV failure: air/O2 14.5% [n = 32]; heliox 14.7% [n = 33]; P = 0.97, and time to NIV failure: heliox group 93 hours [n = 33], air/O2 group 52 hours [n = 32]; P = 0.12). Respiratory rate, pH, PaCO2, and encephalopathy score improved significantly faster with heliox. ICU stay was comparable between the groups. In patients intubated after NIV failed, patients on heliox had a shorter ventilation duration (7.4 ± 7.6 d vs. 13.6 ± 12.6 d; P = 0.02) and a shorter ICU stay (15.8 ± 10.9 d vs. 26.7 ± 21.0 d; P = 0.01). No difference was observed in ICU and 6-month mortality. CONCLUSIONS: Heliox improves respiratory acidosis, encephalopathy, and the respiratory rate more quickly than air/O2 but does not prevent NIV failure. Overall, the rate of NIV failure was low. Clinical trial registered with www.clinicaltrials.gov (NCT 01155310).
RCT Entities:
RATIONALE: During noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work of breathing and hypercapnia more than air/O2, but its impact on clinical outcomes remains unknown. OBJECTIVES: To determine whether continuous administration of heliox for 72 hours, during and in-between NIV sessions, was superior to air/O2 in reducing NIV failure (25-15%) in severe hypercapnic COPD exacerbations. METHODS: This was a prospective, randomized, open-label trial in 16 intensive care units (ICUs) and 6 countries. Inclusion criteria were COPD exacerbations with PaCO2 ≥ 45 mm Hg, pH ≤ 7.35, and at least one of the following: respiratory rate ≥ 25/min, PaO2 ≤ 50 mm Hg, and oxygen saturation (arterial [SaO2] or measured by pulse oximetry [SpO2]) ≤ 90%. A 6-month follow-up was performed. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was NIV failure (intubation or death without intubation in the ICU). The secondary endpoints were physiological parameters, duration of ventilation, duration of ICU and hospital stay, 6-month recurrence, and rehospitalization rates. The trial was stopped prematurely (445 randomized patients) because of a low global failure rate (NIV failure: air/O2 14.5% [n = 32]; heliox 14.7% [n = 33]; P = 0.97, and time to NIV failure: heliox group 93 hours [n = 33], air/O2 group 52 hours [n = 32]; P = 0.12). Respiratory rate, pH, PaCO2, and encephalopathy score improved significantly faster with heliox. ICU stay was comparable between the groups. In patients intubated after NIV failed, patients on heliox had a shorter ventilation duration (7.4 ± 7.6 d vs. 13.6 ± 12.6 d; P = 0.02) and a shorter ICU stay (15.8 ± 10.9 d vs. 26.7 ± 21.0 d; P = 0.01). No difference was observed in ICU and 6-month mortality. CONCLUSIONS:Heliox improves respiratory acidosis, encephalopathy, and the respiratory rate more quickly than air/O2 but does not prevent NIV failure. Overall, the rate of NIV failure was low. Clinical trial registered with www.clinicaltrials.gov (NCT 01155310).
Authors: William Z Zhang; Kazunori Gomi; Seyed Babak Mahjour; Fernando J Martinez; Renat Shaykhiev Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405
Authors: Alain Combes; Daniel Brodie; Nadia Aissaoui; Thomas Bein; Gilles Capellier; Heidi J Dalton; Jean-Luc Diehl; Stefan Kluge; Daniel F McAuley; Matthieu Schmidt; Arthur S Slutsky; Samir Jaber Journal: Intensive Care Med Date: 2022-08-09 Impact factor: 41.787
Authors: J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán Journal: Rev Esp Quimioter Date: 2018-10-04 Impact factor: 1.553